{
  "paper_metadata": {
    "pmid": "36845574",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the TTR gene variant Val142IIe, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.424T>A",
      "protein_notation": "p.Val142Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "76-year-old African American male",
        "phenotype": "mutant ATTR cardiac amyloidosis"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 76,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "presented with dyspnea on exertion and orthopnea, diagnosed with mutant ATTR cardiac amyloidosis",
          "evidence_sentence": "Genetic testing found MYD88 L265P gene mutation, which confirmed the diagnosis of WM."
        }
      ],
      "functional_data": {
        "summary": "Detected a peptide profile consistent with ATTR type amyloid deposition.",
        "assays": [
          "Liquid chromatography\u2013mass spectrometry (LC MS/MS)"
        ]
      },
      "segregation_data": "First-degree relatives were advised to have genetic testing.",
      "population_frequency": "Among patients of African American descent, the reported prevalence of Val142IIe is 1.1\u20139.8%.",
      "evidence_level": "Strong evidence based on clinical presentation and genetic testing.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "No treatment for WM was initiated and he was recommended to follow up with hematologist regularly.",
      "key_quotes": [
        "Formal genetic testing confirmed Val142IIe pathogenic mutation.",
        "Patient was started on tafamidis 61 mg daily for ATTR amyloidosis."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Extracted all relevant information regarding the TTR variant Val142IIe."
  }
}